Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 4
Submit an article Journal homepage
173
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies

Lucas Pacoureaua Assistance Publique - Hôpitaux de Paris, Department of Internal Medicine and Clinical Immunology, Bicetre Hospital, Le Kremlin Bicêtre, France;
,
Mathilde De Menthona Assistance Publique - Hôpitaux de Paris, Department of Internal Medicine and Clinical Immunology, Bicetre Hospital, Le Kremlin Bicêtre, France;
,
Isabelle Boytchevb Assistance Publique - Hôpitaux de Paris, Department of Gastroenterology, Bicetre Hospital, Le Kremlin BIcêtre, France;
,
Thierry Lazurec Assistance Publique - Hôpitaux de Paris, Department of Pathology, Bicetre Hospital, Le Kremlin BIcêtre, France;
,
Laurence Rocherd Assistance Publique - Hôpitaux de Paris, Department of Radiology, Antoine Beclere Hospital, Clamart, France;;e Paris Saclay University, Le Kremlin Bicêtre, France;
,
Olivier Lambottea Assistance Publique - Hôpitaux de Paris, Department of Internal Medicine and Clinical Immunology, Bicetre Hospital, Le Kremlin Bicêtre, France;;e Paris Saclay University, Le Kremlin Bicêtre, France;;f INSERM UMR 1184 Unit, Center for Immunology of Viral and Autoimmune Diseases, Paris Saclay University, Le Kremlin-Bicêtre, France;;g Commissariat à l'Energie Atomique (CEA), Division of Immuno-Virology, IDMIT, Fontenay-aux-Roses, France
&
Nicolas Noëla Assistance Publique - Hôpitaux de Paris, Department of Internal Medicine and Clinical Immunology, Bicetre Hospital, Le Kremlin Bicêtre, France;;e Paris Saclay University, Le Kremlin Bicêtre, France;;f INSERM UMR 1184 Unit, Center for Immunology of Viral and Autoimmune Diseases, Paris Saclay University, Le Kremlin-Bicêtre, France;;g Commissariat à l'Energie Atomique (CEA), Division of Immuno-Virology, IDMIT, Fontenay-aux-Roses, FranceCorrespondence[email protected]
 show all
Pages 984-987 | Received 30 May 2020, Accepted 26 Oct 2020, Published online: 12 Nov 2020

References

  • Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.
  • Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15(10):1090–1099.
  • de Weerdt I, Koopmans SM, Kater AP, et al. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica. 2017;102(10):1629–1639.
  • Vigarios E, Beylot-Barry M, Jegou M-H, et al. Dose-limiting stomatitis associated with ibrutinib therapy: a case series. Br J Haematol. 2019;185(4):784–788.
  • Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–2506.
  • Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018.
  • Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.
  • Louie C, DiMaio M, Matsukuma K, et al. Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides. Am J Surg Pathol. 2015;39(12):1653–1660.
  • Weidner A-S, Panarelli N, Geyer J, et al. Idelalisib-associated colitis: histologic findings in 14 patients. Am J Surg Pathol. 2015;39(12):1661–1667.
  • Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128(2):195–203.
  • Wiestner A. Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2013;31(1):128–130.
  • Aalipour A, Advani RH. Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Ther Adv Hematol. 2014;5(4):121–133.
  • Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175–1184.
  • Weber ANR, Bittner Z, Liu X, et al. Bruton’s tyrosine kinase: an emerging key player in innate immunity. Front Immunol. 2017;8:1454.
  • López-Herrera G, Vargas-Hernández A, González-Serrano ME, et al. Bruton's tyrosine kinase-an integral protein of B cell development that also has an essential role in the innate immune system. J Leukoc Biol. 2014;95(2):243–250.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.